Oxidative Stress-Related Biomarkers in Postmenopausal Osteoporosis: A Systematic Review and Meta-Analyses

Table 3

The relationship of free radicals products/antioxidants and risk of PO.

First author	Biomarker	Biologic sample	Sample (patients/controls)	SMD	Heterogeneity
				(95% CI)		value
Sendur [25]	MDA	Plasma	45 versus 42	0.75 (0.31, 1.19)
Akpolat [24]	MDA	Serum	66 versus 60	1.15 (0.78, 1.53)
Maggio [15]	MDA	Plasma	75 versus 75	−0.16 (−0.48, 0.16)
Wu [33]	MDA	Plasma	60 versus 60	0.29 (−0.07, 0.65)
SMD (95% CI)	MDA	Plasma/serum	246 versus 227	0.43 (0.25, 0.61)	89.9%	<0.0001
Wu [33]	AOPP	Plasma	60 versus 60	1.07 (0.68, 1.45)
Cervellati [6]	AOPP	Serum	30 versus 63	0.09 (−0.32, 0.51)
Cervellati [34]	AOPP	Serum	56 versus 38	0.14 (−0.29, 0.58)
SMD (95% CI)	AOPP	Serum	146 versus 158	0.44 (−0.20, 1.08)	86.3%	0.001
Cervellati [34]	HY	Serum	56 versus 38	0.27 (−0.14, 0.68)
Cervellati [6]	HY	Serum	30 versus 63	0.05 (−0.38, 0.49)
SMD (95% CI)	HY	Serum	96 versus 101	0.17 (−0.13, 0.47)	0%	0.48
Akpolat [24]	NO	Serum	66 versus 60	0.72 (0.36, 1.09)
Sendu [25]	NO	Plasma	45 versus 42	0.60 (0.17, 1.03)
SMD (95% CI)	NO	Plasma/serum	111 versus 102	0.67 (0.40, 0.95)	0%	>0.5
Altindag [21]	TAS	Plasma	39 versus 26	−3.00 (−3.72, −2.28)
Yilmaz [22]	TAS	Plasma	34 versus 15	−84.54 (−101.64, −67.44)
SMD (95% CI)	TAS	Plasma	73 versus 41	−43.30 (−123.21, 36.60)	98.9%	<0.0001
Cervellati [34]	TAP	Serum	56 versus 38	−0.22 ( −0.63, 0.19)
Yousefzadeh [23]	TAP	Plasma	22 versus 22	−0.62 (−1.22, −0.01)
Cervellati [6]	TAP	Serum	30 versus 63	0.04 (−0.40, 0.48)
Sharma [32]	TAP	Serum	35 versus 30	−13.18 (−15.53, −10.83)
SMD (95% CI)	TAP	Serum/plasma	142 versus 150	−2.74 (−4.60, −0.87)	97.5%	<0.0001
Ouzzif [27]	VB12	Plasma	58 versus 64	−0.13 (−0.48, 0.23)
Bozkurt [28],	VB12	Serum	38 versus 48	0.05 (−0.37, 0.48)
Haliloglu [29]	VB12	Serum	25 versus 53	−0.19 (−0.66, 0.29)
Baines [30]	VB12	Serum	110 versus 110	−0.08 (−0.34, 0.19)
Cagnacci [31]	VB12	Serum	28 versus 72	0.46 (0.02, 0.90)
SMD (95% CI)	VB12	Plasma/serum	259 versus 347	−0.00 (−0.20, 0.21)	29.6%	0.224
Haliloglu [29]	Folate	Serum	25 versus 53	−0.46 (−0.94, 0.02)
Baines [30]	Folate	Serum	110 versus 110	−0.39 (−0.66, −0.12)
Cagnacci [31]	Folate	Serum	28 versus 72	−5.52 (−6.41, −4.64)
Bozkurt [28]	Folic Acid	Serum	25 versus 53	0.04 (−0.39, 0.46)
Ouzzif [27]	Folate	Plasma	58 versus 64	−0.24 (−0.60, 0.11)
Akpolat [24]	Folate	Serum	66 versus 60	−1.03 (−1.40, −0.66)
SMD (95% CI)	Folate	Serum/plasma	325 versus 407	−1.18 (−2.04, −0.31)	96.4%	<0.0001
Akpolat [24]	Hcy	Plasma	66 versus 60	0.09 (−0.26, 0.44)
Yilmaz [22]	Hcy	Plasma	34 versus 15	0.25 (−0.36, 0.86)
Ouzzif [27]	Hcy	Plasma	58 versus 64	0.51 (0.14, 0.87)
Bozkurt [28]	Hcy	Serum	38 versus 48	0.43 (−0.00, 0.88)
Haliloglu [29]	Hcy	Serum	25 versus 53	1.15 (0.64, 1.65)
Baines [30]	Hcy	Plasma	110 versus 110	0.24 (−0.03, 0.50)
Cagnacci [31]	Hcy	Serum	28 versus 72	1.22 (0.75, 1.68)
SMD (95% CI)	Hcy	Plasma/serum	359 versus 422	0.53 (0.23, 0.84)	75.3%	<0.0001